Issue link: http://osercommunicationsgroup.uberflip.com/i/668581
C h a i n D r u g s t o r e D a i l y 3 7 M o n d a y, A p r i l 1 8 , 2 0 1 6 Ouchless! ® Plastic, making hospital- grade technology available at home to consumers. Soothe & Cool Soothe & Cool is a hydrating, high water content pad that pulls the heat from the burn while giving moisture back to help the healing process. The hydrogel dressing provides a cooling effect that stops the painful, burning sensation. This bandage covers the burned area of skin for up to five days to promote an ideal healing environ- ment by protecting against dehydration and external contamination. Soothe & Cool works on minor burns, blisters and skin abrasions. QuickStop! When cuts happen, it's instinctual to want to quickly stop the bleeding. If you have a fear of blood or are one of the more than two million people in the U.S. taking blood thinners to avoid the risk of blood clots, QuickStop! offers a quick and natural solution. New technology called M•Doc™, or Micro Dispersed Oxidized Cellulose, is a naturally derived material that speeds up the blood clotting C U R A D (C o nt'd. fro m p. 1 ) process. Available in a bandage or a spray, QuickStop! rapidly absorbs the blood from minor, surface skin injuries and forms a protective layer over the wound. Truly Ouchless! Plastic Last summer, CURAD introduced Truly Ouchless!, a flex fabric line specifically designed with an innovative release adhesive so bandage removal is less painful than typical bandages. Now, Ouchless technology has taken things to the next level with new Truly Ouchless ® Plastic, making it even easier to secure after you've taken a peek at healing wounds and re-apply it. Medline, the parent company of CURAD, is deeply rooted in healthcare and innovation. Medline is a leading expert in advanced wound care and hos- pital advances. CURAD brings advanced technology home by offering innovative solutions for a broad range of health con- cerns. These innovative products won't break the bank and can help take the guesswork out of life's every day emer- gencies. For more information, visit booth #532 or go to www.curad.com. "Acne is difficult to deal with at any time, but becomes even more of a con- cern during prom season," says Erick Estrada, Mentholatum Director of Marketing for Acne Skin Care. "We want to make sure students know that OXY has an effective regimen to get clear skin in time for such a big day." OXY is the first over-the-counter brand acne product to offer a free iOS and Android smartphone app to help teens clear their skin through a tailored regimen. The app features a personalized, dermatologist approved acne skin care regimen, daily tips to help maximize treatment results, daily alerts to ensure that treatment stays on track, and the ability to take before, during and after pictures to show progress. More information about the OXY 28 Day Challenge and its app can be found at www.oxy28daychallenge.com. OXY acne medication has a variety of effective and easy to use forms like pads, face washes and a spot treatment, formulated with clinically proven acne- fighting ingredients, such as benzoyl peroxide (No. 1 active ingredient rec- ommended by dermatologists) and sali- cylic acid, to help clear even the most stubborn acne. The products are designed for teens and can be used for various skin types. "Prom is an important milestone for Mentho latum C o mpany (C o nt'd. fro m p. 1 ) teens and the photos captured will resur- face for years to come," said Erick Estrada. "That's why we're launching the challenge now – to help teens look their best for prom season. We are so confident in both our products and the OXY 28 Day Challenge that we are offering a money back guarantee." More information about OXY can be found on the company website at www.oxyskincare.com, Facebook and Twitter. About The Mentholatum Company The Mentholatum Company is a global health and wellness company, providing non-prescription pharmaceutical, healthcare and cosmetic products to consumers worldwide. Founded in 1889, its focus is on providing quality healthcare solutions for the treatment and prevention of conditions associated with skin care, pain relief and eye care. U.S.A. headquarters are based in Orchard Park, New York. Brands include OXY Acne Medication, pHisoderm ®v Facial Care, Softlips ® Lip Care, Rohto ® Cooling Eye Drops, Hada Labo Tokyo™ Skin Care, WellPatch ® Pain Relieving Patches, Deep Heating ® Pain Relief, Mentholatum ® Ointment, Fletcher's ® Laxative and Red Cross ® Oral Care. For more information, visit booth #504 or go to www.mentholatum.com. the workforce. Millennials now make up the largest generation in the labor force. Their rise, combined with the retirement of the baby boomers and the dearth of experienced Gen X leaders, means that traditional talent strategies are fast becoming obsolete. CDD: What should companies do to attract talent now? JBK: Become an employer of choice, which means improving workplace cul- ture. New research from Deloitte shows that millennials believe businesses should put employees first, and now that the recession has ended, candidates across generations are also holding out for employers with talent-friendly cul- tures. CDD: How do companies create that kind of culture? JBK: Start by asking yourself some sim- ple questions about your workplace envi- ronment and how it might improve. For example, 'How am I currently showing respect and appreciation for my employ- ees?' There is a short list of questions together with a fuller discussion of cul- ture in my book, "From My Bad to My Best: How Individuals and Companies Can Differentiate Themselves in the Age of Mediocrity." CDD: How should retention strategies change? JBK: Millennials think that businesses are not doing enough to create a new generation of leaders, according to Deloitte, so development is crucial. Of particular urgency are the gaps created every day as 10,000 baby boomers reach retirement age. Just 15 percent of organ- JB K A sso ciates (C o nt'd. fro m p. 1 ) izations currently have a strong bench, and less than half of critical positions can be filled immediately, on average, according to research from The Conference Board and DDI. Companies without strong succession plans put themselves at serious risk. CDD: How do companies fill senior positions while developing future millen- nial leaders? JBK: Companies need to look seriously at non-traditional candidates, hiring more for potential than for experience and con- sidering candidates from different indus- tries, backgrounds, processes, countries or cultures. It is possible to find and keep diverse talent, but you have to make an effort. You've got to integrate multi-gen- erational work styles, building loyalty from the people who will work every minute they're awake to the talented executives who demand flexibility, while still maintaining engagement and over- sight. CDD: How does JBK Associates International help? JBK: We serve as a management con- sulting company for anything that has to do with talent – recruiting, develop- ing, nurturing, engaging and making the most of the people who are so criti- cal for success in today's business cli- mate. Anybody can put bodies in chairs, but that's not what we're about. Our full-service talent management business team develops a deep under- standing of each client's culture, indus- try and workforce to deliver future leaders who will succeed in that envi- ronment. For more information, go to www.jbk associates.net, call 201.567.9070 or email info@jbkassociates.net. BIOSIG TECHNOLOGIES ANNOUNCES ADVANCED RESEARCH PROGRAM WITH MAYO CLINIC BioSig Technologies, Inc. has announced the establishment of an advanced research program with Dr. Samuel Asirvatham at Mayo Clinic in Rochester, Minnesota. This program has been designed to build upon the initial studies conducted at Mayo Clinic in March, June and November 2015 through a tripling of investment to fully characterize and devel- op novel features discovered during this prior preclinical work. These features have the potential to make a significant impact in the treatment of complex arrhythmias. "We are extremely pleased to contin- ue our sponsored research activities with Dr. Asirvatham and his colleagues at Mayo Clinic," said Greg Cash, President and Chief Executive Officer of BioSig Technologies. "The previous studies con- firmed the potential of PURE EP to improve the clarity of cardiac signals while minimizing electrical noise in the cardiac electrophysiology laboratory." About BioSig Technologies BioSig Technologies is a medical device company that is developing a proprietary technology platform designed to improve the $4 billion EP marketplace. Led by a proven management team and a veteran, independent Board of Directors, Minneapolis-based BioSig Technologies is preparing to commercialize its PURE EP™ System. The PURE EP System is a surface electrocardiogram and intracardiac mul- tichannel signal acquisition and analysis system designed to assist electrophysiol- ogists in making clinical decisions in real-time by acquiring and displaying high-fidelity cardiac signal recordings and providing clarity of data which may be used to guide the electrophysiologists in identifying ablation targets – areas of tissue to treat that otherwise create a heart rhythm disturbance (arrhythmia). Analysts forecast the global market for EP devices will grow at a 12.1 percent compound annual growth rate, from $2.5 billion in 2012 to $5.5 billion by 2019, making it one of the fastest growing med- ical device segments. Just in the U.S., the number of Atrial Fibrillation (AF) and Ventricular Tachycardia (VT) arrhythmia ablations is forecast to grow at 10.5 per- cent from 2012 to 2017. BioSig intends to seek FDA 510(k) clearance for the PURE EP System. The company has achieved proof of concept validation through UCLA labs, and has performed pre-clinical studies at the Mayo Clinic in Minnesota. The company is collaborating with several of the nation's most prestigious cardiac arrhyth- mia centers, including Texas Cardiac Arrhythmia Institute, UCLA Cardiac Arrhythmia Center and Mayo Clinic. For more information, visit www.biosigtech.com.